Astellas Pharma Inc

This study tested a new drug called gilteritinib alongside standard chemotherapy in 97 adults newly diagnosed with acute myeloid leukemia (AML), including those with a specific genetic change (FLT3 mutation). The first part aimed to find the safest dose, and the second part measu…

This study tested a new medicine called ASKP1240 in 50 people who just received a kidney transplant. The goal was to see how the drug moves through the body and if it is safe. Participants received a single dose of the drug or a placebo. The study is complete and helps researcher…

This study tested whether adding a second drug (OSI-906) to the standard maintenance drug erlotinib could help control advanced non-small cell lung cancer (NSCLC) longer than erlotinib alone. It included 205 adults whose cancer had not worsened after initial chemotherapy. The goa…

This study tested the drug enzalutamide in 395 men with advanced prostate cancer that had spread and was no longer controlled by standard hormone therapy. Participants had not yet received chemotherapy. The goal was to see if enzalutamide could delay the rise of PSA levels, a mar…

This study tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) helps people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. 88 participants who had not received prior chemotherapy were randomly …

This study tested a medicine called fezolinetant to see if it can reduce hot flashes in Japanese women going through menopause. About 410 women took either a low or high dose of the drug or a placebo (fake pill) daily for 12 weeks. They tracked their hot flashes using a smartphon…

This study tested a medicine called fezolinetant to see if it is safe for Japanese women going through menopause who have hot flashes. 277 women took either the drug or a placebo daily for up to a year. The goal was to check for side effects and how well the body handles the trea…